Otros idiomas Duality Biotherapeutics, Inc.

Acciones

9606

KYG2929M1087

Farmacéuticos

Mercado cerrado - Hong Kong S.E. Otros sitios de cotización 10:08:30 11/06/2026			Variación 5 días	Varia. 1 de enero.
179,10 ^HKD	+1,47 %		-10,54 %	-39,94 %

26/05	Duality Biotherapeutics, Inc. (SEHK:9606) inicia un plan de recompra de acciones por 8,803,626 títulos, representativos del 10% de su capital social emitido, bajo la autorización aprobada el 20 de junio de 2025.	CI
20/05	Duality Biotherapeutics lanza una recompra de acciones de 40 millones de dólares; los títulos suben un 3%	MT

Otros idiomas

26/05	Duality Biotherapeutics, Inc. commences an Equity Buyback Plan for 8,803,626 shares, representing 10% of its issued share capital, under the authorization approved on June 20, 2025.
20/05	Duality Biotherapeutics Launches $40 Million Stock Buyback; Shares Rise 3%
19/05	Duality Biotherapeutics announces share repurchase plan of up to $40 million
13/04	Duality Biotherapeutics approved proposed RMB share issue on sci-tech board
09/04	DualityBio Announces China NMPA Acceptance of Biologics License Application Seeking Approval for Trastuzumab Pamirtecan for the Treatment of Unresectable or Metastatic HER2-Positive Adult Breast Cancer
09/04	DualityBio Announces China NMPA Acceptance of Biologics License Application Seeking Approval for Trastuzumab Pamirtecan for the Treatment of Unresectable or Metastatic HER2-Positive Adult Breast Cancer
09/04	Duality Biotherapeutics' Biologics License Application for Breast Cancer Drug Accepted in China
09/04	Duality Biotherapeutics says NMPA accepts biologics license application for DB-1303/BNT323
24/03	DualityBio (9606.HK) Announces 2025 Annual Results
24/03	Duality Biotherapeutics' Loss Widens in 2025; Appoints CFO; Shares Lose 3%
23/03	Duality Biotherapeutics FY revenue rmb1.85 billion
23/03	Duality Biotherapeutics Inc says Si Wen tendered resignation as exec director
23/03	Duality Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
23/03	Duality Biotherapeutics, Inc. Announces Board and Committee Changes, with Effect from March 23, 2026
23/03	Duality Biotherapeutics, Inc. Appoints ZHANG Shaoren as Chief Financial Officer, with Effect from March 23, 2026
24/02	Duality Biotherapeutics Says DB-1311 Shows Signs of Activity in Early-Stage Prostate Cancer Study
23/02	Duality Biotherapeutics, Inc. Announces Update on Efficacy and Safety Results from Core Product Db-1311/Bnt324 At Asco Genitourinary Cancers 2026
20/10/25	Duality Biotherapeutics Board OKs Sci-Tech Board Listing on Shanghai Bourse; Shares Rise 5%
17/10/25	Duality Biotherapeutics proposes issue of RMB shares & listing on the Sci-Tech-Board of the Shanghai Stock Exchange
14/10/25	Certain Ordinary Shares of Duality Biotherapeutics, Inc. are subject to a Lock-Up Agreement Ending on 14-OCT-2025.
22/09/25	Duality Biotherapeutics, Inc.(SEHK:9606) added to S&P Global BMI Index
08/09/25	Duality Biotherapeutics to Join Hang Seng Index
05/09/25	Duality Biotherapeutics' Trial of Breast Cancer Drug Reaches Primary Endpoint
05/09/25	BioNTech erreicht Meilenstein bei Entwicklung von Krebsmittel
05/09/25	BioNTech, Duality score initial trial win with breast cancer precision drug